Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination gene therapy for glioblastoma involving herpes simplex virus vector-mediated codelivery of mutant IkappaBalpha and HSV thymidine kinase.

Cancer gene therapy - 1 May 2005

Moriuchi Shusuke, Glorioso Joseph C, Maruno Motohiko, Izumoto Shuichi, Wolfe Darren, Huang Shaohua, Cohen Justus B, Yoshimine Toshiki

Abstract excerpt

To improve the effectiveness of herpes simplex virus (HSV) thymidine kinase/ganciclovir (HSV-tk/GCV) suicide gene therapy, the replication-defective HSV vector TOIkappaB expressing both HSV-TK and a mutant form of the NF-kappaB inhibitor IkappaBalpha (IkappaBalphaM) was developed. TOIkappaB was constructed by recombining the IkappaBalphaM gene into the U(L)41 locus of a replication-defective lacZ expression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Caspase 3
Share to Caspases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Glioblastoma

Share to Herpesvirus 1, Human

Share to I-kappa B Proteins

Share to NF-KappaB Inhibitor alpha

Share to Thymidine Kinase

Source

Identifiers

PMID: 15692608
DOI: 10.1038/sj.cgt.7700816

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination gene therapy for glioblastoma involving herpes simplex virus vector-mediated codelivery of mutant IkappaBalpha and HSV thymidine kinase.PMID 15692608Read ↗

Oncolytic herpes simplex virus vectors for cancer virotherapy.Semantic proximity Read ↗

T-Cell-Mediated Killing in Glioblastoma Organoids induced by Adenoviral Delivery of the CIITA TransgeneSemantic proximity Read ↗

Combination of anti-cancer drug therapy with targeted gene therapy against glioblastomaSemantic proximity Read ↗

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomasSemantic proximity Read ↗

Sitimagene Ceradenovec: A Gene-Based Drug for the Treatment of Operable High-Grade GliomaSemantic proximity Read ↗

Improved Herpes Simplex Virus Type 1 Amplicon Vectors for Proportional Coexpression of Positron Emission Tomography Marker and Therapeutic GenesSemantic proximity Read ↗

Multi-targeted neuroprotection by the HSV-2 gene ICP10PK includes robust bystander activity through PI3-K/Akt and/or MEK/ERK-dependent neuronal release of vascular endothelial growth factor and fractalkine.Semantic proximity Read ↗

Enhancement of antitumor activity of herpes simplex virus gamma(1)34.5-deficient mutant for oral squamous cell carcinoma cells by hexamethylene bisacetamide.Semantic proximity Read ↗

Multitracer positron emission tomographic imaging of exogenous gene expression mediated by a universal herpes simplex virus 1 amplicon vector.Semantic proximity Read ↗

Effect of Herpes Simplex Virus Thymidine Kinase Expression Levels on Ganciclovir-Mediated Cytotoxicity and the “Bystander Effect”Semantic proximity Read ↗

Potential of adenoviral p53 gene therapy and irradiation for the treatment of malignant gliomas.Semantic proximity Read ↗

A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.